Longitudinal Association Between Generalized Anxiety Disorder and Cognitive Change: A Meta-Analysis
Psychiatry Investigation · 25.05.2026 · 23 (5) · 588-596
DOI: 10.30773/pi.2025.0299 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Psychiatry Investigation, erschienen am 25.05.2026. Verfasst von Jie Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aimed to systematically evaluate the longitudinal relationship between generalized anxiety disorder (GAD) and cognitive function changes. Specifically, we examined whether GAD is an independent risk factor for sustained cognitive decline and explored the potential effects of cognitive behavioral therapy (CBT) on cognitive and emotional outcomes.
Methods
We conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library for eligible longitudinal studies and randomized controlled trials published up to January 20, 2025. Meta-analyses were performed using RevMan 5.4.1. Effect sizes were estimated using mean differences (MD) and 95% confidence intervals. Heterogeneity was assessed with the I2 statistic. Sensitivity analyses and publication bias assessments were also conducted.
Results
A total of 13 studies were included. The results showed no significant differences between GAD patients and controls on memory and attention subscores of the dementia rating scale (p>0.05). Total error scores also showed no significant difference. Subgroup analyses indicated that GAD patients receiving CBT demonstrated greater improvement in clinical symptoms than those receiving non-cognitive interventions (MD=-4.39, p=0.0004). Beck Depression Inventory score differences were statistically significant, while Penn State Worry Questionnaire score differences were not.
Conclusion
This meta-analysis suggests that while GAD does not show consistent evidence of sustained cognitive decline, CBT may be associated with improvement in emotional symptoms. By integrating longitudinal data with treatment outcomes, this study offers preliminary insights into the potential indirect cognitive benefits of psychotherapy in GAD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
- Department of Radiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
- School of Healthcare Management, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Department of Social Services, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
- Medical Data Science Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Department of Radiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. zzza00509@btch.edu.cn.
Zitieren
APA
Li, J., Shi, L., Jiang, N., Zhao, B., Wang, Y., & Zheng, Z. (2026). Longitudinal Association Between Generalized Anxiety Disorder and Cognitive Change: A Meta-Analysis. Psychiatry Investigation, 23(5), 588-596. https://doi.org/10.30773/pi.2025.0299
Vancouver
Li J, Shi L, Jiang N, Zhao B, Wang Y, Zheng Z. Longitudinal Association Between Generalized Anxiety Disorder and Cognitive Change: A Meta-Analysis. Psychiatry Investigation. 2026;23(5):588-596. doi:10.30773/pi.2025.0299
BibTeX
@article{Li2026,
author = {Li, Jie and Shi, Leiyu and Jiang, Nan and Zhao, Benqi and Wang, Yujie and Zheng, Zhuozhao},
title = {Longitudinal Association Between Generalized Anxiety Disorder and Cognitive Change: A Meta-Analysis},
journal = {Psychiatry Investigation},
year = {2026},
volume = {23},
number = {5},
pages = {588--596},
doi = {10.30773/pi.2025.0299}
}
EUVIMED